Spyre Therapeutics, Inc (SYRE)

Spyre Therapeutics' stock price has significantly increased, approximately 284.02% over the past year, influenced by several events. The company reported its Q4 2025 and Q3 2025 earnings, and a public offering in October 2025 raised $316.2 million. Positive interim Phase 1 results for two next-generation TL1A antibodies were reported, and the Phase 2 SKYLINE-UC platform study was initiated, with the Phase 2 SKYWAY-RD basket study upcoming. The SKYWAY Phase 2 trial for SPY072 completed rheumatoid arthritis enrollment ahead of schedule, and SPY001 for ulcerative colitis is on track for a Q2 2026 proof-of-concept readout. CEO Cameron Turtle's $740K insider sale drew some scrutiny after shares surged significantly.

As a clinical-stage biotechnology company, Spyre Therapeutics' products are not yet widely commercialized, so direct demand seasonality for its products and services is not a relevant factor. However, analysis of SYRE's historical stock price data suggests some seasonality in stock performance, with August showing the highest probability of positive returns and April the lowest.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD) and rheumatic diseases. The company's primary products are monoclonal antibodies (mAbs) designed to target specific markers involved in immune-mediated diseases, with a pipeline including extended half-life antibodies targeting alpha4beta7 integrin, tumor necrosis factor-like ligand 1A (TL1A), and interleukin 23 (IL-23). Spyre Therapeutics aims to redefine the standard of care for these chronic inflammatory conditions by optimizing antibody half-life and potency, and through rational therapeutic combinations.

Spyre Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States, and was incorporated in Delaware. Information regarding a broader international geographic footprint for its operations or market reach is not explicitly detailed in the available data.

Spyre Therapeutics has maintained a generally positive brand reputation, particularly among analysts, with a consensus "Buy" rating from Wall Street analysts. Analysts from firms like Stifel Nicolaus, BTIG Research, Leerink Partners, and Wells Fargo & Company cover the stock, with several holding bullish price targets and listing SYRE as a top pick for 2026. The company's focus on developing long-acting antibodies and combination therapies for IBD and rheumatic diseases is seen as having substantial clinical potential, and while the CEO's insider sale drew some scrutiny, it does not appear to have significantly tarnished the overall positive sentiment.

Spyre Therapeutics, Inc. has a diverse ownership structure, with a significant portion held by institutional investors, ranging from 79.15% to 90.37%. Insiders hold between 7.34% and 32.82%, while public companies and individual investors hold a smaller percentage, from 0.00% to 11.22%. Major institutional owners include Fmr LLC, BlackRock, Inc., Rtw Investments, Lp, Vanguard Group Inc, Fairmount Funds Management LLC, VR Adviser, LLC, Capital International Investors, Perceptive Advisors Llc, Driehaus Capital Management Llc, and Commodore Capital Lp. Fairmount Funds Management LLC is the largest individual shareholder, owning 14.30 million shares, representing 18.21% of the company, and FMR LLC owns 12% as of November 2025.